Recommandations pour la réalisation des examens d’immuno-hématologie de première intention par les laboratoires médicaux

IF 1.4 4区医学 Q4 HEMATOLOGY

Transfusion Clinique et Biologique Pub Date : 2025-02-01 DOI:10.1016/j.tracli.2024.10.004

Patrick Joubaud , Jean-Marc Giannoli

{"title":"Recommandations pour la réalisation des examens d’immuno-hématologie de première intention par les laboratoires médicaux","authors":"Patrick Joubaud , Jean-Marc Giannoli","doi":"10.1016/j.tracli.2024.10.004","DOIUrl":null,"url":null,"abstract":"<div><div>The main objective of these recommendations for good practices is to supplement the regulatory provisions of the decree of May 15, 2018 which sets the conditions for performing erythrocyte immunohematology tests in medical biology, in order to clarify their application for medical laboratories which conduct first-line immunohematology tests: erythrocyte phenotyping and detection of anti-erythrocyte antibodies. These recommendations cover all phases of a biological examination (pre-analytical, analytical, and post-analytical) as defined in the Public Health Code (Article L6211-2).</div><div>Four levels of recommendations have been established:</div><div>● Recommended practices: complying with the requirements of the NF EN ISO 15189:2022 standard and ensuring optimal medical service delivery.</div><div>● Acceptable practices: situations which deviate from the best practices in immunohematology but still ensuring satisfactory patient management as well as transfusion and obstetrical safety.</div><div>● Non-recommended practices: not complying with the requirements of the NF EN ISO 15189:2022 standard and not allowing satisfactory patient management, but ensuring transfusion and obstetrical safety.</div><div>● Unacceptable practices: presenting a risk for transfusion or obstetrical complications.</div><div>Compliance with these recommendations optimizes patient medical care, particularly in transfusion or obstetrical contexts.</div></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":"32 1","pages":"Pages 87-111"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Clinique et Biologique","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1246782024001046","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The main objective of these recommendations for good practices is to supplement the regulatory provisions of the decree of May 15, 2018 which sets the conditions for performing erythrocyte immunohematology tests in medical biology, in order to clarify their application for medical laboratories which conduct first-line immunohematology tests: erythrocyte phenotyping and detection of anti-erythrocyte antibodies. These recommendations cover all phases of a biological examination (pre-analytical, analytical, and post-analytical) as defined in the Public Health Code (Article L6211-2).

Four levels of recommendations have been established:

● Recommended practices: complying with the requirements of the NF EN ISO 15189:2022 standard and ensuring optimal medical service delivery.

● Acceptable practices: situations which deviate from the best practices in immunohematology but still ensuring satisfactory patient management as well as transfusion and obstetrical safety.

● Non-recommended practices: not complying with the requirements of the NF EN ISO 15189:2022 standard and not allowing satisfactory patient management, but ensuring transfusion and obstetrical safety.

● Unacceptable practices: presenting a risk for transfusion or obstetrical complications.

Compliance with these recommendations optimizes patient medical care, particularly in transfusion or obstetrical contexts.

查看原文本刊更多论文

关于医学实验室进行一线免疫血液学检测的建议。

这些良好操作建议的主要目的是对2018年5月15日法令的监管规定进行补充，该法令规定了在医学生物学中进行红细胞免疫血液学检验的条件，以明确其对进行一线免疫血液学检验（红细胞表型和抗红细胞抗体检测）的医学实验室的适用性。这些建议涵盖了《公共卫生法》（第 L6211-2 条）中规定的生物检查的所有阶段（分析前、分析中和分析后）。建议分为四个等级：推荐实践：符合 NF EN ISO 15189:2022 标准的要求，确保提供最佳医疗服务。可接受的实践：偏离免疫血液学最佳实践的情况，但仍能确保令人满意的患者管理以及输血和产科安全。非推荐做法：不符合 NF EN ISO 15189:2022 标准的要求，无法对患者进行满意的管理，但仍能确保输血和产科安全。不可接受的操作：存在输血或产科并发症风险。遵守这些建议可优化患者医疗护理，尤其是在输血或产科情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Clinique et Biologique 医学-免疫学

CiteScore

2.50

自引率

11.80%

发文量

234

审稿时长

36 days

期刊介绍： Transfusion Clinique et Biologique, the official journal of the French Society of Blood Transfusion (SFTS): - an aid to training, at a European level - the only French journal indexed in the hematology and immunology sections of Current Contents Transfusion Clinique et Biologique spans fundamental research and everyday practice, with articles coming from both sides. Articles, reviews, case reports, letters to the editor and editorials are published in 4 editions a year, in French or in English, covering all scientific and medical aspects of transfusion: immunology, hematology, infectious diseases, genetics, molecular biology, etc. And finally, a convivial cross-disciplinary section on training and information offers practical updates. Readership: "Transfusers" are many and various: anesthetists, biologists, hematologists, and blood-bank, ICU and mobile emergency specialists...